Venous thrombosis: Who should be screened for thrombophilia in 2014?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 1-2, 2014, Pages 65-69

  Kyrle, Paul A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Recurrence; Thrombophilia screening; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; D DIMER; FIBRINOGEN; HOMOCYSTEINE; MARKER; PHOSPHOLIPID ANTIBODY; PLACEBO; PROTHROMBIN; THROMBIN; VITAMIN B GROUP; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; BLOOD LEVEL; CASE CONTROL STUDY; CLINICAL DECISION MAKING; EXPERIMENTAL THERAPY; GAIN OF FUNCTION MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; LABORATORY; LABORATORY TEST; LEG VEIN; POPULATION; PROPHYLAXIS; PROSPECTIVE STUDY; PROTEIN S DEFICIENCY; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCREENING; SYSTEMATIC REVIEW (TOPIC); THROMBOPHILIA; THROMBOSIS PREVENTION; UNITED KINGDOM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION; WILD TYPE; COMPLICATION; FEMALE; MALE; MASS SCREENING; RECURRENT DISEASE; UNNECESSARY PROCEDURE; UTILIZATION; VENOUS THROMBOSIS;

ANTICOAGULANTS; FEMALE; HUMANS; MALE; MASS SCREENING; RECURRENCE; RISK FACTORS; THROMBOPHILIA; UNNECESSARY PROCEDURES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84894185693     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2083     Document Type: Review

References (24)

1. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005; 365: 1163-1174.
2. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010; 376: 2032-2039.
3. Kearon C, Akl EA, Comerota AJ, et al.; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e419S-494S.
4. van den Belt AG, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997; 157: 2227-2232.
5. De Stefano V, Simioni P, Rossi E, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica. 2006; 91: 695-698.
6. Brouwer JL, Lijfering WM, Ten Kate MK, et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost. 2009; 101: 93-99.
7. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol. 2005; 25: 1992-1997.
8. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005; 293: 2352-2361.
9. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999; 81: 14-17.
10. Eichinger S, Weltermann A, Mannhalter C, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med. 2002; 162: 2357-2360.
11. Prandoni P, Tormene D, Spiezia L, et al. Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. J Thromb Haemost. 2008; 6: 2223-2224.
12. Ho WK, Hankey GJ, Quinlan DJ, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006; 166: 729-736.
13. Marchiori A, Mosena L, Prins MH, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica. 2007; 92: 1107-1114.
14. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009; 301: 2472-2485.
15. Lijfering WM, Middledorp S, Veeger NJ, et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation. 2010; 121: 1706-1712.
16. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000; 343: 457-462.
17. Eichinger S, Stümpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998; 80: 566-569.
18. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood. 2007; 109: 139-144.
19. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998; 104: 332-338.
20. Garcia D, Akl EA, Carr R, et al. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013; 122: 817-824.
21. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003; 362: 523-526.
22. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349: 631-639.
23. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005; 3: 848-853.
24. Eischer L, Gartner V, Schulman S, et al. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Ann Hematol. 2009; 88: 485-490.